이박시온 바이오텍(EVAX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.34 (+4.02%), 시가총액 $0.03B, 52주 범위 $1.71 ~ $11.01.
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to targe
이박시온 바이오텍의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
이박시온 바이오텍의 현재 주가는 $3.34 (+4.02%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
이박시온 바이오텍의 시가총액은 약 $0.03B입니다.
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the